Skip to main content
Giant Biogene Holding Co., Ltd logo

Giant Biogene Holding Co., Ltd — Investor Relations & Filings

Ticker · 2367 ISIN · KYG3887G1091 LEI · 391200HMPBKVFGL0V252 HKEX Manufacturing
Open in API
Filings indexed 173 across all filing types
Latest filing 2026-05-06 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 2367

About Giant Biogene Holding Co., Ltd

http://www.xajuzi.com

Giant Biogene Holding Co., Ltd. is a biotechnology enterprise specializing in the research, development, manufacture, and distribution of professional skin treatment products and bioactive ingredients. The company utilizes proprietary synthetic biology platform technology to produce core components, primarily recombinant collagen and high-purity rare ginsenosides. Its recombinant collagen portfolio includes full-length and functionally enhanced variants engineered to be 100% identical to human collagen sequences. Giant Biogene applies these ingredients across three primary sectors: functional skincare products (under brands like Cofoe and Collgen), medical devices (including advanced injectable implants), functional foods, and special medical purpose formula foods. This technological focus establishes the company as a leader in bioactive ingredient-based professional skin care.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 April 2026
Regulatory Filings Classification · 100% confidence The document is a detailed monthly return report for an equity issuer listed on the Hong Kong Stock Exchange, specifically under Chapter 19B of the Exchange Listing Rules. It includes movements in authorised and issued share capital, share options, repurchases, and confirmations related to compliance with listing rules. The document is regulatory in nature, providing updates on share capital and shareholding movements rather than financial performance or management commentary. It does not contain financial statements, earnings data, or management discussion. It is not an announcement of a report but a regulatory filing required by the exchange. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2026-05-06 English
FORM OF PROXY FOR USE AT 2025 ANNUAL GENERAL MEETING TO BE HELD ON 28 MAY 2026
AGM Information Classification · 95% confidence The document is a 'Form of Proxy' for the 2025 Annual General Meeting (AGM) of Giant Biogene Holding Co., Ltd. It includes instructions for shareholders to appoint proxies to vote on various resolutions at the AGM, including receiving the annual financial statements, re-electing directors, appointing auditors, granting share repurchase and issuance mandates, and declaring dividends. The document is not the actual AGM materials or presentations but a proxy voting form related to the AGM. Therefore, it is classified as AGM Information (AGM-R). The document length (7027 characters) supports it being a detailed proxy form rather than a brief announcement or other filing type.
2026-05-06 English
NOTICE OF ANNUAL GENERAL MEETING
AGM Information Classification · 100% confidence The document is a notice of an Annual General Meeting (AGM) for Giant Biogene Holding Co., Ltd. It includes details about the meeting date, location, agenda items such as receiving audited financial statements, re-election of directors, appointment of auditors, share repurchase and allotment mandates, and dividend declarations. The document is clearly labeled as a "NOTICE OF ANNUAL GENERAL MEETING" and contains no actual financial statements or detailed financial analysis, but rather the agenda and resolutions to be voted on at the AGM. This fits the definition of AGM Information (AGM-R), which includes presentations and materials shared during the AGM. The document length is over 11,000 characters, indicating it is not a brief announcement but a full notice. Therefore, the appropriate classification is AGM Information (AGM-R).
2026-05-06 English
PROPOSED RE-ELECTION OF DIRECTORS PROPOSED CHANGE OF AUDITORS PROPOSED GRANT OF GENERAL MANDATES TO REPURCHASE SHARES AND ISSUE SHARES PROPOSED DECLARATION AND DISTRIBUTION OF FINAL DIVIDENDS AND SPEC
AGM Information Classification · 95% confidence The document is a circular issued by Giant Biogene Holding Co., Ltd dated 6 May 2026, containing detailed information about the upcoming Annual General Meeting (AGM) scheduled for 28 May 2026. It includes proposed re-election of directors, proposed change of auditors, proposed general mandates to repurchase and issue shares, proposed declaration and distribution of dividends, and the notice of the AGM itself. The document is comprehensive and includes appendices with details of directors and explanatory statements on share repurchase mandates. The content is typical of a circular sent to shareholders ahead of an AGM to inform them of the agenda and resolutions to be voted on. It is not a transcript, earnings release, or standalone audit report, nor is it a simple announcement or proxy solicitation. The presence of the notice of AGM and detailed proposals related to the AGM indicates this is an AGM Information document, specifically a circular related to the AGM. Therefore, the appropriate classification is AGM Information (AGM-R). The document length (15,000 characters) and detailed content support this classification with high confidence.
2026-05-06 English
PROPOSED CHANGE OF AUDITORS
Board/Management Information Classification · 95% confidence The document is an announcement regarding the proposed change of auditors for Giant Biogene Holding Co., Ltd. It discusses the retirement of the current auditor (Ernst & Young) and the recommendation to appoint a new auditor (KPMG). The announcement references the upcoming Annual General Meeting (AGM) where the appointment will be voted on. It does not contain any financial statements or audit reports themselves, but rather is a corporate governance announcement about auditor changes. This fits the category of Board/Management Information (MANG), which includes announcements of changes in company senior management or board-related matters such as auditor appointments. The document length is over 6,000 characters and contains detailed reasoning and background, not just a brief notice, supporting a confident classification as MANG rather than a simple Regulatory Filing or Report Publication Announcement.
2026-04-30 English
2025 Environmental, Social and Governance (ESG) Report
Environmental & Social Information Classification · 100% confidence The document is titled '2025 Environmental, Social and Governance (ESG) Report' and covers the company's ESG governance structure, management systems, practical measures, and performance for the year 2025. It includes detailed sections on governance, R&D, quality management, supply chain, customer services, environmental management, social welfare, and more. The report explicitly states it is prepared in compliance with the ESG Reporting Guide of the Hong Kong Stock Exchange. The content focuses on ESG factors rather than financial performance or regulatory compliance. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. Therefore, this document fits the category of Environmental & Social Information (ESG) report.
2026-04-29 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.